Core B_Silvestri

核心B_Silvestri

• 批准号: 10339441
• 负责人: Guido Silvestri
• 金额: $ 106.08万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-04 至 2026-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10339441
• 关键词: Acquired Immunodeficiency Syndrome; Adherence; Adult; Animal Model; Animals; Antigens; Appearance; Autopsy; B-Lymphocytes; Behavior; Blood; Bone Marrow; Breeding; CD4 Positive T Lymphocytes; Caring; Cell Count; Cells; Chemistry; Clinical; Collection; Complete Blood Count; Complex; Control Animal; Data; Data Analyses; Data Collection; Desire for food; Dose; Eating; Ensure; Evaluation; Feces; Fine needle aspiration biopsy; Funding; Genetic; Goals; HIV; HIV Infections; HIV vaccine; Health; Health Status; Histocompatibility Antigens Class I; Housing; Human Resources; Immune response; Immunization; Immunologic Monitoring; Immunologic Surveillance; Immunologics; Immunology; Infection; Infrastructure; Intervention; Longitudinal Studies; Macaca mulatta; Microbiology; Mission; Modeling; Monitor; Movement; Physical Examination; Plasma; Play; Positioning Attribute; Prevention approach; Prevention strategy; Primates; Procedures; Protocols documentation; Quality Control; Reagent; Research; Research Design; Research Project Grants; Research Proposals; Role; SIV; Sampling; Serology; Ships; Simian T-lymphotropic virus 1; Structure of germinal center of lymph node; Substance administration; Techniques; Technology; Testing; Time; Tissues; Tuberculin Test; United States National Institutes of Health; Universities; Vaccine Clinical Trial; Vaccines; Veterinarians; Viral; Viral Load result; Viral Pathogenesis; Virus Diseases; Work; alertness; animal care; animal resource; base; clinically relevant; efficacy testing; experience; experimental study; immunogenicity; in vivo; innovation; lymph nodes; member; neutralizing antibody; nonhuman primate; novel; pre-clinical; preclinical trial; programs; protective allele; response; sample collection; simian human immunodeficiency virus; success; vaccine candidate; vaccine response; vaccine strategy; vaccine trial

Nonhuman primates (NHP) specifically, rhesus macaques (RMs), are a key animal model in investigating prevention strategies of HIV infection. This animal model of simian immunodeficiency virus (SIV)/ simian-human immunodeficiency virus (SHIV) infection has been utilized to elucidate both basic concepts in immunization and evaluate clinically relevant prevention approaches. RMs are ideal for investigating the humoral and cellular responses generated by HIV candidate immunizations and the impact on acquisition of infection. NHP studies require extensive coordination, expertise, personnel, and infrastructure. Therefore, the NHP Core (Core B) will support this HIVRAD research team by executing the four preclinical RM immunization studies proposed in Project 1. The animals will receive a variety of novel candidate immunogens and vaccine strategies. Their immune responses will be monitored throughout the study via collection of blood and tissues. Dependent upon those results, potentially, a select few animals will undergo viral challenge with SHIV to test the efficacy of the immunizations. Core B will support the success of this research program by 1) ensuring the adherence to regulatory approvals and procedures necessary for NHP research; 2) coordination of animal selection, assignment, substance administration and sample collection; 3) proper storage and shipment of all samples to the collaborating PIs and Cores; 4) coordination of data collection, analysis, and distribution; 5) and ensuring the monitoring of animal health over the course of the studies. This NHP core will work closely with the collaborators for the vaccine and challenge studies and will participate actively in the scientific mission of this HIVRAD. Further, it will ensure that all NHP research is integrated with the goals of this proposal and the evolving needs of the studies. Core B is led by Dr. Guido Silvestri, who has >20 years of experience leading NHP research projects involving complex study design and intervention, specifically, he has executed a large number of collaborative pre-clinical vaccine trials. During this research he was essential in investigating and developing novel sample collection techniques, such as lymph node fine needle aspirates, for the continued monitoring of germinal center responses during longitudinal studies. Core B will be based at Yerkes National Primate Research Center (YNPRC) at Emory University, this NIH-funded primate research center possesses all the proper animal resources and state-of-the-art veterinarian care expertise necessary to support the proposed work. As an integral part of this research program, the NHP Core will provide critical support to achieve the shared objectives of evaluating these proposed promising novel pre-clinical vaccines.

非人类灵长类动物（NHP）特别是恒河猕猴（RMS），是研究的关键动物模型 艾滋病毒感染的预防策略。这种动物模型的猿猴免疫缺陷病毒（SIV）/猿猴人类模型 免疫缺陷病毒（SHIV）感染已被用来阐明免疫中的基本概念和 评估临床相关的预防方法。 RMS是研究体液和细胞的理想选择 艾滋病毒候选免疫产生的反应以及对感染获得的影响。 NHP研究 需要广泛的协调，专业知识，人员和基础设施。因此，NHP核心（核心B）将 通过执行提出的四个临床前RM免疫研究来支持这个Hivrad研究团队 项目1。动物将获得各种新型候选免疫原和疫苗策略。他们的 在整个研究中，通过收集血液和组织，将监测免疫反应。取决于 这些结果可能会在SHIV中受到少数动物的挑战，以测试 免疫接种。核心B将通过1）确保遵守该研究计划的成功 NHP研究所需的监管批准和程序； 2）选择动物的协调， 分配，物质给药和样品收集； 3）所有样品的正确存储和运输 合作的PI和核心； 4）数据收集，分析和分布的协调； 5）并确保 在研究过程中监测动物健康。该NHP核心将与合作者紧密合作 进行疫苗和挑战研究，并将积极参与此Hivrad的科学任务。更远， 它将确保所有NHP研究都与该提案的目标和不断发展的需求相结合 研究。 Core B由Guido Silvestri博士领导，他拥有超过20年的NHP研究项目经验 涉及复杂的研究设计和干预，特别是他执行了大量协作 临床前疫苗试验。在这项研究中，他对于研究和开发新样本至关重要 收集技术，例如淋巴结细针抽吸，用于继续监测生发中心 纵向研究期间的反应。核心B将位于Yerkes国家灵长类动物研究中心 （YNPRC）在埃默里大学（Emory University），这个由NIH资助的灵长类动物研究中心拥有所有合适的动物 支持拟议工作所需的资源和最先进的兽医护理专业知识。作为一个积分 NHP核心将提供一部分研究计划的一部分，将提供关键的支持，以实现 评估这些提出的有前途的新型临床前疫苗。